| Trodelvy | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | Phase 3 | Active not recruiting | 443 | Feb 2027 |
| Tilpisertib Fosmecarbil | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 2 | Active not recruiting | 176 | Jan 2027 |
| anitocabtagene-autoleucel | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Phase 2 | Active not recruiting | 136 | Dec 2026 |
| CAL101 | A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | 150 | Nov 2026 |
| Filgotinib | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | Phase 3 | Completed | 1,173 | Sep 8, 2026 |
| Trodelvy | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) | Phase 2 | Active not recruiting | 193 | Sep 2026 |
| Domvanalimab | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | Phase 2 | Active not recruiting | 100 | Aug 2026 |
| Lenacapavir Tablet | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) | Phase 2 | Active not recruiting | 253 | Jul 2026 |
| sofosbuvir/velpatasvir | Expanding the Pool in Orthotopic Heart Transplantation | Phase 2 | Completed | 20 | Jun 2, 2026 |
| Livdelzi | Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) | Phase 3 | Completed | 96 | May 6, 2026 |
| Tecartus | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | 95 | Mar 25, 2026 |
| lenacapavir | Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated | Phase 3 | Terminated | 73 | Mar 16, 2026 |
| Descovy or Truvada | SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder | Phase 3 | Completed | 40 | Feb 27, 2026 |
| Edecesertib | Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Terminated | 20 | Dec 17, 2025 |
| Yescarta | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | Phase 2 | Completed · results | 35 | Nov 24, 2025 |
| Epclusa | A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients | Phase 2 | Completed | 201 | Jul 15, 2025 |
| Trodelvy | Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 3 | Completed · results | 711 | Jul 4, 2025 |
| Tecartus | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | Phase 2 | Completed · results | 95 | Jun 17, 2025 |
| Filgotinib | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | Phase 3 | Completed · results | 2,731 | May 16, 2025 |
| Obeldesivir | Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection | Phase 2 | Terminated · results | 150 | May 8, 2025 |
| Obeldesivir | Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection | Phase 2 | Terminated · results | 4 | Apr 16, 2025 |
| sofosbuvir/velpatasvir | The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients | Phase 2 | Completed · results | 5 | Mar 17, 2025 |
| Tecartus | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | Phase 2 | Terminated · results | 19 | Jan 27, 2025 |
| Trodelvy | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | Phase 2 | Terminated · results | 4 | Oct 15, 2024 |
| co-formulated 25mg TAF/ 200mg FTC | The Women TAF-FTC Benchmark Study | Phase 3 | Completed · results | 54 | Dec 19, 2023 |
| Tecartus | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) | Phase 2 | Completed · results | 105 | Sep 22, 2023 |
| Veklury | Trial of Treatments for COVID-19 in Hospitalized Adults | Phase 3 | Completed | 1,552 | Jul 9, 2022 |
| Idelalisib | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | Phase 2 | Completed · results | 27 | Oct 6, 2020 |
| Cabotegravir Oral Tablet | Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men | Phase 3 | Completed · results | 4,570 | May 14, 2020 |
| F/TAF | Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection | Phase 3 | Terminated · results | 5,399 | Jan 31, 2019 |
| Sofosbuvir | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC | Phase 3 | Completed | 150 | Dec 2017 |
| emtricitabine / tenofovir disoproxil fumarate / raltegravir . | Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients | Phase 2 | Completed · results | 30 | Dec 2015 |
| Arhalofenate | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout | Phase 2 | Completed | 32 | Dec 2014 |
| Arhalofenate | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout | Phase 2 | Completed | 67 | Nov 2011 |
| MBX-2982 | Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes | Phase 2 | Completed | 100 | Aug 2010 |
| MBX-102 | Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin | Phase 2 | Terminated | 242 | Feb 2010 |
| CLEVUDINE IN ASSOCIATION TENOFOVIR | ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy | Phase 3 | Terminated | 150 | Dec 14, 2008 |
| Veklury | Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection | Phase 3 | Terminated · results | — | Not stated |
| Filgotinib | Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis | Phase 2 | Terminated · results | — | Not stated |
| emtricitabine, FTC (drug) | Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART | Phase 3 | Completed | 350 | Not stated |